InflaRx NV Stock Quote IFRX - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

1.365

Bid

1.35

Ask

1.37

Volume

88,433

1.27 Day's Range 1.3775

1.14 52 Week Range 5.20

Market Cap

74.138M

Previous Close

1.26

Open

1.27

Last Trade

1.36

Last Trade Time

13:37:03

Financial Volume

$ 114,612

VWAP

1.296

Average Volume (3m)

235,979

Shares Outstanding

54,115,530

Dividend Yield

PE Ratio

-1.74

Earnings Per Share (EPS)

-0.79

Revenue

63k

Net Profit

-42.67M

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator in... InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.inflarx.de

Headquarters

Jena, Deu

Founded

1970

InflaRx NV is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IFRX. The last closing price for InflaRx NV was $1.26. Over the last year, InflaRx NV shares have traded in a share price range of $ 1.14 to $ 5.20.

InflaRx NV currently has 54,115,530 shares outstanding. The market capitalization of InflaRx NV is $74.14 million. InflaRx NV has a price to earnings ratio (PE ratio) of -1.74.

InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans

InflaRx will focus development activities and resources initially on selected indications in immuno-dermatology, with registrational-phase vilobelimab and potentially best-in-class oral C5aR...

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...

InflaRx Appoints Jan Medina as Head of Investor Relations

JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients

InflaRx to cover costs of GOHIBIC for patients who are treated in line with its Emergency Use Authorization (EUA) but do not survive. InflaRx is determined to support broader access to GOHIBIC for...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904

MAD pharmacokinetic and pharmacodynamic data support best-in-class potential of INF904 over tested dose range of 30 mg once per day (QD) to 90 mg twice per day (BID) for 14 days: Achieved ≥90...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.175	-11.3636363636	1.54	1.55	1.24	188458	1.34798652	CS
4	-0.165	-10.7843137255	1.53	1.68	1.24	237151	1.49970519	CS
12	-0.165	-10.7843137255	1.53	1.92	1.24	235979	1.57514284	CS
26	-0.885	-39.3333333333	2.25	2.35	1.14	328775	1.54374717	CS
52	-2.885	-67.8823529412	4.25	5.2	1.14	283688	2.64833849	CS
156	-2.275	-62.5	3.64	7.2499	0.7762	667326	3.91868505	CS
260	-49.015	-97.2905915046	50.38	53.1	0.7762	707822	4.3892632	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
TWGTop Wealth Group Holding Ltd	$ 3.205 (73.24%)	24.48M
SHOTWSafety Shot Inc	$ 0.48 (60.00%)	6.58k
EGOXNext e GO NV	$ 0.0533 (48.06%)	315.42M
NKGNNKGen Biotech Inc	$ 1.25 (45.35%)	1.31M
MNDRMobile health Network Solutions	$ 29.251 (43.60%)	6.25M
YYAIConnexa Sports Technologies Inc	$ 0.9801 (-53.11%)	11.25M
SBFMSunshine Biopharma Inc	$ 1.90 (-42.77%)	9.08M
IPDNProfessional Diversity Network Inc	$ 1.11 (-33.93%)	140.39k
ICUSeaStar Medical Holding Corporation	$ 0.4061 (-24.80%)	4.86M
BGLCBioNexus Gene Lab Corporation	$ 0.6445 (-24.05%)	583.28k
EGOXNext e GO NV	$ 0.054 (50.00%)	315.25M
SQQQProShares UltraPro Short QQQ	$ 12.6457 (4.77%)	141.24M
AGBAAGBA Group Holding Ltd	$ 1.26 (22.33%)	116.04M
SINTSiNtx Technologies Inc	$ 0.0451 (12.75%)	93.09M
BSFCBlue Star Foods Corporation	$ 0.0851 (32.14%)	76.27M